Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Articles online first > Minerva Gastroenterologica e Dietologica 2015 Oct 22

CURRENT ISSUEMINERVA GASTROENTEROLOGICA E DIETOLOGICA

A Journal on Gastroenterology, Nutrition and Dietetics


Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

Minerva Gastroenterologica e Dietologica 2015 Oct 22

language: English

Supplementary management of benign prostatic hypertrophy with Prostaquil. An 8-week registry

Belcaro G., Dugall M., Luzzi R., Ledda A., Pellegrini L., Hosoi M., Errichi B. M., Francis S., Cornelli U.

Department of Biomedical Sciences, Irvine3 Labs, Circulation Sciences, Chieti-Pescara University, Italy


PDF  REPRINTS


The aim of this registry was to evaluate the management of initial symptoms of benign prostatic hyperthrophy (BPH) in otherwise healthy subjects, using Prostaquil® (Alchem) in a 8-week registry. Prostaquil was used at the dosage of 200 mg/day. The product includes Pygeum extract (100 mg) and Saw palmetto oil (35 mg). The two resulting groups standard management and supplement) were comparable.
RESULTS: No side effects or comparability problems were observed and compliance was optimal with more than 95% of the capsules correctly used. Empting, frequency, intermittency, urgency, weak flow, straining, nocturia were all significantly improved with Prostaquil (p<0.05) and the improvement – globally and evaluating any single item - was significantly superior to the one observed in controls (p<0.05). Quality of life with the supplement was also significantly better in comparison with controls (p<0.05). The residual vescical volume was 94.7;5,8 ml in the supplement group at inclusion and decreased to 39.3;5 ml (p<0.05) at 8 weeks. This decrease was equivalent to a reduction of 58.5%(vs a decrease of 27.9% in controls)(p<0.05; ANOVA).
In conclusion, the most common symptoms of BPH are controlled by Prostaquil a new standardized supplement including Pygeum.

top of page